Stability of attention deficits in schizophrenia

Schizophrenia Research

Volumn 91, Issue 1-3, 2007, Pages 107-111

  Harris, Josette G ^a   Minassian, Arpi ^b   Perry, Willliam ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics; Attention; Neuropsychological; Schizophrenia

Indexed keywords

ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MENTAL CONCENTRATION; MENTAL PATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL STATUS;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HOSPITALIZATION; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR;

EID: 33847352974     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.12.021     Document Type: Article

References (23)

1. Benton A.L., Hamsher K.des., Varney N.R., and Spreen O. Contributions to Neuropsychological Assessment (1983), Oxford University Press, New York
2. Brickenkamp R., and Zillmer E. d2 Test of Attention. 1st U.S. ed. (1998), Hogrefe & Huber, Gottingen
3. Elevag B., and Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14 (2000) 1-21
4. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0) (1997), Biometrics Research Department, New York State Psychiatric Institute, New York
5. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper T., Kosten T.R., and Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26 (2002) 75-85
6. Goldberg T.E., and Weinberger D.R. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J. Clin. Psychiatry 57 suppl 9 (1996) 62-65
7. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., and Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 162 (1993) 43-48
8. Goldstein G. Cognitive heterogeneity in psychopathology: the case of schizophrenia. In: Vernon P.A. (Ed). The Neuropsychology of Individual Differences (1994), Academic Press, San Diego, CA 209-233
9. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
10. Gur R., Kohler C., Ragland J.D., Siegel S.J., Bilker W.B., Loughead J., Phend N., and Gur R.C. Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. Neuropsychopharmacology 28 11 (2003) 2029-2036
11. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., and Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34 (1993) 702-712
12. Harris J.G., Adler L.E., Young D.A., Cullum C.M., Rilling L.M., Cicerello A., Intemann P.M., and Freedman R. Neuropsychological dysfunction in parents of schizophrenics. Schizophr. Res. 20 (1996) 253-260
13. Harris J.G., Kongs S., Allensworth D.A., Sullivan B., Zerbe G., and Freedman R. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 29 (2004) 1378-1385
14. Harvey P.D. Ziprasidone and cognition: the evolving story. J. Clin. Psychiatry 64 suppl 19 (2003) 33-39
15. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., and Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 58 1 (2001) 24-32
16. Lee M.A., Thompson P.A., and Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 49 (1994) 271-277
17. Levin E.D., Wilson W., Rose J., and McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 15 (1996) 429-436
18. Lezak M.D., Howieson D.B., and Loring D.W. Neuropsychological Assessment. 4th ed. (2004), Oxford University Press, New York
19. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., and Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry 157 (2000) 767-771
20. Liu S.K., Chen W.J., Chang C.-J., and Lin H.-N. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia. Neuropsychopharmacology 22 (2000) 311-319
21. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25 (1999) 233-255
22. Weickert T.W., Goldberg T.E., Marenco S., Bigelow L.B., Egan M.F., and Weinberger D.R. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 28 8 (2003) 1491-1500
23. Yee C.M., Nuechterlein K.H., Morris S.E., and White P.M. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J. Abnorm. Psychology 107 4 (1998) 691-698